Pfizer's bacteria prevention vaccine fails at main stage

There are no vaccines yet to prevent the illness caused by Clostridioides difficile (C. diff) bacterium, which has been classified as an urgent public health threat by the U.S. Centers for Disease Control and Prevention.

The infection is associated with diarrhea that may progress to a severe and debilitating illness and even result in death. Most C. diff cases occur when patients have been taking antibiotics, which wipe out friendly bacteria in the colon that normally keep C. diff under control.

The Pfizer vaccine only showed an efficacy of 31% in preventing the infections after the third dose, and 28.6% following the second dose in the study.

Read Also- Pfizer supplemental application for ABRILADA interchangeability accepted by USFDA for review

For infections recorded 14 days after the third dose, vaccine efficacy was 49% at 12 months, 47% at 24 months and 31% at final analysis.

But Pfizer said it would evaluate next steps as the trial showed the vaccine helped reduce the severity of infections.

"We are encouraged by the promising potential benefit observed against more severe C. difficile infection, as a large portion of cases lead to extended diarrhea episodes that can require hospitalization," said Pfizer's head of vaccine research and development, Kathrin Jansen.

Read Also - Pfizer COVID vaccine approved in South Korea for 5-11 years old

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. With manufacturing sites placed strategically around the world, Pfizer is able to ensure an uninterrupted supply of vital medicines, vaccines, and their components, at competitive prices. Located in places that give us a logistical advantage, our facilities maintain our high standards for safety and efficacy.